ResearcherUniversity of SienaNo recent work listed

Daniele Marrelli

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-2066-1618; OpenAlex author ID A5079842683. Sources: OpenAlex.

Their work

Papers: 2 (first author 0, last author 1)
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 4

Papers, trials and grants by year

2013: 1 paper · 2014: none · 2015: 1 paper

Papers 2

Gemcitabine, oxaliplatin, and capecitabine (GEMOXEL) compared with gemcitabine alone in metastatic pancreatic cancer: a randomized phase II study. Co-author DOI 10.1007/s00280-015-2683-1 ↗
Pancreatic adenocarcinoma in duodenal ectopic pancreas: a case report and review of the literature. Last author PMID 23946982 ↗

Closest collaborators

The 4 strongest of 4 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Roberto Petrioli · 1 shared paper, 2015 · strength 0.06
- Paper Gemcitabine, oxaliplatin, and capecitabine (GEMOXEL) compared with gemcitabine alone in metastatic pancreatic cancer: a… DOI 10.1007/s00280-015-2683-1 ↗
Giandomenico Roviello · 1 shared paper, 2015 · strength 0.06
- Paper Gemcitabine, oxaliplatin, and capecitabine (GEMOXEL) compared with gemcitabine alone in metastatic pancreatic cancer: a… DOI 10.1007/s00280-015-2683-1 ↗
Edoardo Francini · 1 shared paper, 2015 · strength 0.06
- Paper Gemcitabine, oxaliplatin, and capecitabine (GEMOXEL) compared with gemcitabine alone in metastatic pancreatic cancer: a… DOI 10.1007/s00280-015-2683-1 ↗
Alessandro Ginori · 1 shared paper, 2013 · strength 0.04
- Paper Pancreatic adenocarcinoma in duodenal ectopic pancreas: a case report and review of the literature. PMID 23946982 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.